Your browser doesn't support javascript.
loading
Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma.
Song, Yan; Park, Paul M C; Wu, Lei; Ray, Arghya; Picaud, Sarah; Li, Deyao; Wimalasena, Virangika K; Du, Ting; Filippakopoulos, Panagis; Anderson, Kenneth C; Qi, Jun; Chauhan, Dharminder.
Afiliación
  • Song Y; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Park PMC; Department of Cancer Biology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Wu L; Department of Cancer Biology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Ray A; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Picaud S; University of Oxford, Oxford, UK.
  • Li D; Department of Cancer Biology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Wimalasena VK; Department of Cancer Biology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Du T; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Filippakopoulos P; University of Oxford, Oxford, UK.
  • Anderson KC; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Kenneth_Anderson@dfci.harvard.edu.
  • Qi J; Department of Cancer Biology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA, USA. Jun_Qi@dfci.harvard.edu.
  • Chauhan D; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Dharminder_Chauhan@dfci.harvard.edu.
Leukemia ; 33(11): 2685-2694, 2019 11.
Article en En | MEDLINE | ID: mdl-30962579
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Péptidos y Proteínas de Señalización Intracelular / Inhibidores de Proteasoma / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Péptidos y Proteínas de Señalización Intracelular / Inhibidores de Proteasoma / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos